Ionis Pharmaceuticals IONS Interest expense and penalties, net (benefit)/charge recognized
Interest expense and penalties, net (benefit)/charge recognized at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized?
- Ionis Pharmaceuticals (IONS) reported interest expense and penalties, net (benefit)/charge recognized of $25K in Q4 2025.
- How has Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized changed year-over-year?
- Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized decreased by 0.0% year-over-year, from $25K to $25K.
- What is the long-term trend for Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized has grown at a 0.0% compound annual growth rate (CAGR), from $100K to $100K.
- What does interest expense and penalties, net (benefit)/charge recognized mean?
- The cost of interest and penalties associated with uncertain tax positions.
- How do you interpret interest expense and penalties, net (benefit)/charge recognized?
- An increase signals higher potential financial exposure to tax authorities for past or current tax positions.
- How does interest expense and penalties, net (benefit)/charge recognized compare across companies?
- Standard component of tax contingency disclosures for all large corporations.